Incorporating innovative B-cell targeting therapeutics into a combined-modality bridging approach followed by timely consolidative haploidentical transplantation to salvage a pediatric patient with relapsed/refractory diffuse large B-cell lymphoma

被引：0
|
作者：
Chao, Yu-Ju [1 ]
Lee, Pei-Ing [2 ]
Yang, Tzu-Hsien [3 ]
Fang, Li-Hua [4 ]
Tsai, Yu-Chun [5 ]
Lee, Ming-Yuan [6 ]
Wang, Yun-Hsin [7 ]
Chen, Liuh-Yow [3 ]
Chen, Rong-Long [1 ]
机构：
[1] Koo Fdn Sun Yat Sen Canc Ctr, Dept Pediat Hematol & Oncol, Taipei, Taiwan
[2] Koo Fdn Sun Yat Sen Canc Ctr, Dept Nucl Med, Taipei, Taiwan
[3] Acad Sinica, Inst Mol Biol, Taipei, Taiwan
[4] Koo Fdn Sun Yat Sen Canc Ctr, Dept Pharm, Taipei, Taiwan
[5] Koo Fdn Sun Yat Sen Canc Ctr, Dept Radiat Oncol, Taipei, Taiwan
[6] Koo Fdn Sun Yat Sen Canc Ctr, Dept Pathol, Taipei, Taiwan
[7] Koo Fdn Sun Yat Sen Canc Ctr, Dept Mol Med, Taipei, Taiwan
来源：
PEDIATRIC BLOOD & CANCER | 2024年
关键词：
NON-HODGKIN-LYMPHOMA; CHILDREN; CHEMOTHERAPY; ADOLESCENTS; RITUXIMAB; THERAPY; SCT;
D O I：
10.1002/pbc.31289
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Efficacy of salvage radiotherapy for relapsed/refractory diffuse large B-cell lymphoma
    Wang, Shu-Bei
    Chen, Jia-Yi
    Zhao, Wei-Li
    Kirova, Youlia M.
    Cao, Wei-Guo
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 (04) : 1019 - 1026
  • [2] Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma
    Lu, Q.
    Huang, H.
    Tang, S.
    Wang, Y.
    Yang, D-H
    DRUGS OF TODAY, 2021, 57 (09) : 571 - 580
  • [3] Novel agents in relapsed/refractory diffuse large B-cell lymphoma
    Varma, Gaurav
    Goldstein, Jordan
    Advani, Ranjana H.
    HEMATOLOGICAL ONCOLOGY, 2023, 41 : 92 - 106
  • [4] Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma
    Kato, Koji
    Sugio, Takeshi
    Ikeda, Takashi
    Yoshitsugu, Kanako
    Miyazaki, Kana
    Suzumiya, Junji
    Yamamoto, Go
    Kim, Sung-Won
    Ikegame, Kazuhiro
    Uehara, Yasufumi
    Mori, Yasuo
    Ishikawa, Jun
    Hiramoto, Nobuhiro
    Eto, Tetsuya
    Nakazawa, Hideyuki
    Kobayashi, Hikaru
    Serizawa, Kentaro
    Onizuka, Makoto
    Fukuda, Takahiro
    Atsuta, Yoshiko
    Suzuki, Ritsuro
    BONE MARROW TRANSPLANTATION, 2024, 59 (03) : 306 - 314
  • [5] Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma
    Malecek, Mary-Kate
    Watkins, Marcus P.
    Bartlett, Nancy L.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 831 - 839
  • [6] New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma
    Moore, Donald C.
    Peery, Matthew R.
    Tobon, Katherine A.
    Raheem, Farah
    Hwang, Grace S.
    Alhennawi, Lin
    Hughes, Mitchell E.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (08) : 1848 - 1858
  • [7] ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma
    Alderuccio, Juan Pablo
    Sharman, Jeff P.
    BLOOD REVIEWS, 2022, 56
  • [8] Developing New Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Barca, Eva Gonzalez
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (23)
  • [9] Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Sehn, Laurie H.
    Herrera, Alex F.
    Flowers, Christopher R.
    Kamdar, Manali K.
    McMillan, Andrew
    Hertzberg, Mark
    Assouline, Sarit
    Kim, Tae Min
    Kim, Won Seog
    Ozcan, Muhit
    Hirata, Jamie
    Penuel, Elicia
    Paulson, Joseph N.
    Cheng, Ji
    Ku, Grace
    Matasar, Matthew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) : 155 - +
  • [10] Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
    Salles, Gilles
    Dlugosz-Danecka, Monika
    Ghesquieres, Herve
    Jurczak, Wojciech
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (04) : 455 - 463
12345